1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2Tate SC, Sykes AK, Kulanthaivel P, et al. A population pharmacokinetic and pharmacodynamic analysis of abemaciclib in a phase I clinical trial in cancer patients. Clin Pharmacokinet. 2018;57(3):335-344. http://dx.doi.org/10.1007/s40262-017-0559-8
3Chigutsa E, Kambhampati SRP, Sykes AK, et al. Development and application of a mechanistic population modeling approach to describe abemaciclib pharmacokinetics. CPT Pharmacometrics Syst Pharmacol. 2020;9(9):523-533. https://doi.org/10.1002/psp4.12544
4Groenland SL, Martínez-Chávez A, van Dongen MGJ, et al. Clinical pharmacokinetics and pharmacodynamics of the cyclin-dependent kinase 4 and 6 inhibitors palbociclib, ribociclib, and abemaciclib. Clin Pharmacokinet. 2020;59 (12):1501-1520. https://doi.org/10.1007/s40262-020-00930-x